Equilibrative and Concentrative Transport Mechanisms

Principles of Clinical Pharmacology

Volumn , Issue , 2007, Pages 197-227

  Preusch, Peter C ^a  

^a NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882541787     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369417-1/50054-7     Document Type: Chapter

References (192)

1. Pharma SNP Consortium of the Japan Pharmaceutical Manufacturers Association. (Internet at http://www.jpma.or.jp/12english/publications/pub019b_genome;http:/.
2. Ishikawa T, Tsuji A, Inui K, Sai Y, Anzai N, Wada M, et al. The genetic polymorphism of drug transporters: Functional analysis approaches. Pharmacogenomics 2004, 5:189-199.
3. SNP Consortium Ltd. (Internet at http://snp.cshl.org.).
4. National Center for Biotechnology Information Entrez SNP interface. (Internet at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Limits&DB=snp.).
5. International HapMap Project The International HapMap Consortium. The International HapMap Project. Nature 2003, 426:789-796. Internet at. http://www.hapmap.org/index.html.en.
6. Pang DC, Amidon GL, Preusch PC, Sadée W. Second AAPS-NIH frontier symposium: Membrane transporters drug therapy. American Association of Pharmaceutical Sciences. AAPS PharmSci 1999, 1:E7. Internet at. http://www.aapsj.org/view.asp?art=ps010205.
7. AAPS workshop on drug transporters in ADME: From bench to bedside 2005, 1157-1159.
8. A biennial meeting on membrane transporters in drug delivery and drug targeting has been orga-nized by Matthias Hediger 2005, 1999, 2001, 2003 Programs available Internet at. http://www.bioparadigms.org/conference/index.htm.
9. Membrane transporters as drug targets 1999, Kluwer Academic/Plenum Publishers, New York. A. GL, S.-A. W (Eds.).
10. Friedman MH Principles and models of biological transport 1986, Springer-Verlag, New York.
11. Stein WD Channels, carriers, and pumps: An introduction to membrane transport 1990, Academic Press, New York.
12. Hancock REW Bacterial transport as an import mechanism and target for antimicrobials. Drug transport in antimi-crobial and anticancer chemotherapy 1995, 1204-1210. Marcel Dekker, Inc., New York. G. NH (Ed.).
13. Van Winkle LJ Biomembrane transport 1999, Academic Press, San Diego.
14. Fournier RL Basic transport phenomena in biomed-ical engineering 1999, Taylor & Frances Publishers, Philadelphia.
15. Lakshminarayanaiah N Equations of membrane biophysics 1984, Academic Press, New York.
16. Hager WD, Fenster P, Mayersohn M, Perrier D, Graves P, Marcus FI, et al. Digoxin-quinidine inter-action. N Engl J Med 1979, 300:513-517.
17. Bassolino-Klimas D, Alper HE, Stouch TR. Solute diffusion in lipid bilayer membranes: An atomic level study by molecular dynamics simulation. Biochem-istry 1993, 32:1494-1501.
18. Bassolino D, Alper H, Stouch TR. Drug-membrane interactions studied by molecular dynamics simula-tion: Size dependence of diffusion. Drug Des Discov 1996, 13:334-339.
19. Bemporad D, Essex JW, Luttmann C. Permeation of small molecules through a lipid bilayer: A computer simulation study. J Phys Chem B 2004, 108:S156-S162.
20. Bemporad D, Luttmann C, Essex JW. Computer sim-ulation of small molecule permeation across a lipid bilayer: Dependence on bilayer properties solute volume size and cross-sectional area. Biophys J 2004, 87:519-525.
21. Hansch C, Leo A Exploring QSAR fundamentals and applications in chemistry and biology 1995, American Chemical Society, Washington, DC.
22. Austel B, Kutter R Absorption, distribution, and metabolism of drugs. Quantitative structure/activity relationships. Medicinal chemistry monographs 1983, vol 19:787-791. Academic Press, New York. T. JG (Ed.).
23. Yang CY, Cai SJ, Liu H, Pidgeon C Immobilized artificial membranes - screens for drug membrane interactions. Adv Drug Del. Rev 1997, 23:708-717.
24. Ong S, Liu H, Pidgeon C. Immobilized artificial mem-brane chromatography: Measurements of membrane partition coefficient and predicting drug membrane permeability. J Chromatogr A 1996, 728:521-526.
25. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to esti-mates solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997, 23:141.
26. Chopra I Tetracycline uptake and efflux in bacteria. Drug transport in antimicrobial and anticancer chemotherapy 1995, 2129-2139. Marcel Dekker, Inc., New York. G. NH (Ed.).
27. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) -methacylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic. Clin Cancer Res 1999, 5:265-270.
28. Abdellaoui K, Boustta M, Morjani H, Vert M. Uptake and intracellular distribution of 4-amino-fluorescein-labelled poly (L-lysine citramide imide) in K562 cells. J Drug Target 1998, 5:39-42.
29. Swaan PW. Recent advances in intestinal macro-molecular drug delivery via receptor-mediated trans-port pathways. Pharm Res 1998, 15:1690-1698.
30. Schentag JJ, Jusko WJ, Vance JW, Cumbo TJ, Abrutyn E, DeLattre M, Gerbracht LM. Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm 1977, 5:2285-2293.
31. Whelton A, Solez K. Aminoglycoside nephrotoxic-ity -a tale of two transports. J Lab Clin Med 1982, 99:E7.
32. Bennett WM, Plamp CE, Elliott WC, Parker RA, Porter GA. Effect of basic amino acids and amino-glycosides on 3H-gentamicin uptake in cortical slices of rat and human kidney. J Lab Clin Med 1982, 99:7-9.
33. Atkinson AJ Jr Gentamicin kinetics: A simulation case study. Principles of pharmacokinetic data analysis: Modeling and simulation (workshop manual) 2004, SAAM Institute, Inc, Seattle. F. DM, A. AJ Jr (Eds.).
34. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminogly-cosides: Review and recommendations for clinical practice. J Antimicrob Chemother 1997, 39:289-306.
35. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D. Aminoglycoside toxicity: Daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004, 38:1238-1241.
36. Nagai J, Takano M. Molecular aspects of renal han-dling of aminoglycosides and strategies for prevent-ing the nephrotoxicity. Drug Metab Pharmacokinet 2004, 19:12624-12637.
37. Tran Ba Huy P, Bernard P, Schacht J. Kinetics of gen-tamicin uptake release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest 1986, 77:135-141.
38. de Jager P, van Altena R. Hearing loss and nephro-toxicity in long-term aminoglycoside treatment of patients with tuberculosis. Int J Tuberc Lung Dis 2002, 6:4875-4884.
39. Bickel U, Pardridge WM. Vector-mediated delivery of opiod peptides to the brain. NIDA Res Monogr 1995, 154:1-13.
40. Pardridge WM, Wu D, Sakane T. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neur. Pharm Res 1998, 15:437-496.
41. Pardridge WM. Blood-brain barrier drug targeting: The future of brain drug development. Mol Interv 2003, 3:229-256.
42. Pardridge WM. Blood-brain barrier drug targeting: The future of brain drug development. Mol Interv 2003, 3:51.
43. Russell-Jones GJ. The potential use of receptor-mediated endocytosis for oral drug delivery. Adv Drug Deliv Rev 2001, 46:113-128.
44. McCarthy KM, Yoong Y, Simister NE. Bidirectional transcytosis of IgG by the rat neonatal Fc recep-tor expressed in a rat kidney cell line: A system to study protein transport across epithelia. J Cell Sci 2000, 113:3-25.
45. Apodaca G, Mostov KE. Transcytosis of placen-tal alkaline phosphatase-polymeric immunoglobulin receptor fusion proteins is regulated by mutations of Ser664. J Biol Chem 1993, 268:221-244.
46. Perez F, Joliot A, Bloch-Gallego E, Zahraoui A, Triller A, Prochiantz A. Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide. J Cell Sci 1992, 102:83-94.
47. Han K, Jeon MJ, Kim KA, Park J, Choi SY. Effi-cient intracellular delivery of GFP by homeodomains of Drosophila Fushi-tarazu and Engrailed proteins. Mol Cells 2000, 10:193-206.
48. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001, 19:826-834.
49. Ford KG, Souberbielle BE, Darling D, Farzaneh F. Protein transduction: An alternative to genetic inter-vention?. Gene Ther 2001, 8:559-577.
50. Mi Z, Mai J, Lu X, Robbins PD. Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo. Mol Ther 2000, 2:148-155.
51. Vives E. Cellular uptake of the Tat peptide: An endo-cytosis mechanism following ionic interactions. J Mol Recognit 2003, 16:156-162.
52. Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K. Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding. J Biol Chem 2003, 278:677-686.
53. Green I, Christison R, Voyce CJ, Bundell KR, Lindsay MA. Protein transduction domains: Are they delivering?. Trends Pharmacol Sci 2003, 24:1538-1544.
54. Dietz GP, Bahr M. Delivery of bioactive molecules into the cell: The Trojan horse approach. Mol Cell Neurosci 2004, 27:159-170.
55. Chen L, Wright LR, Chen CH, Oliver SF, Wender PA, Mochly-Rosen D. Molecular transporters for pep-tides: Delivery of a cardioprotective e-PKC agonist peptide into cells intact ischemic heart using a transport system R (7). Chem Biol 2001, 8:1492-1500.
56. Gratton JP, Yu J, Griffith JW, Babbitt RW, Scotland RS, Hickey R, Giordano FJ, Sessa WC. Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat Med 2003, 9:622-627.
57. Stevenson BR, Keon BH. The tight junction: Mor-phology to molecules. Annu Rev Cell Dev Biol 1998, 14:28-46.
58. Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol 2003, 81:576-582.
59. Ward PD, Tippin TK, Thakker DR. Enhancing paracellular permeability by modulating epithe-lial tight junctions. Pharm Sci Technol Today 2000, 3:90-105.
60. Thanou M, Florea BI, Langemeyer MW, Verhoef JC, Juninger HE. N-Trimethylated chitosan chloride (TMC) improves the intestinal permeation of the pep-tide drug buserelin in vitro (Caco-2 cells) and in vivo (rats). Pharm Res 2000, 17:51.
61. Lee HJ, Zhang Y, Pardridge WM. Blood-brain barrier disruption following the internal carotid arterial per-fusion of alkyl glycerols. J Drug Target 2002, 10:59-73.
62. Cox DS, Raje S, Gao HL, Salama NN, Eddington ND. Enhanced permeability of molecular weight markers poorly bioavailable compounds across Caco-2 cell monolayers using the absorption enhancer zonula occludens t. Pharm Res 2002, 19:1277-1285.
63. Salama NN, Fasano A, Thakar M, Eddington ND. The effect of Δ G on the transport and oral absorption of macromolecules. J Pharm Sci 2004, 93:23712-23719.
64. Salama NN, Fasano A, Thakar M, Eddington ND. The impact of Δ G on the oral bioavailability of low bioavailable therapeutic agents. J Pharmacol Exp Ther 2005, 312:717-722.
65. Fei Y-J, Ganapathy V, Leibach F. Molecular and structural features of the proton-coupled oligopep-tide transporter superfamily. Prog Nucleic Acid Res Mol Biol 1998, 58:728-732.
66. +-dependent nucleo-side transporters. Pharm Res 1997, 14:1173-1176.
67. Cass CE Nucleoside transport. Drug transport in anti-microbial and anticancer chemotherapy 1995, 1-4. Marcel Dekker, Inc., New York. G. NH (Ed.).
68. Zhang L, Brett CM, Giacomini KM. Role of organic cation transporters in drug absorption and elimination. Annu Rev Pharmacol Toxicol 1998, 38:339-347.
69. Silverman JA, Schrenk D. Hepatic canalicular mem-brane 4: Expression of the multidrug resistance genes in the liver. FASEB J 1997, 11:265-271.
70. Muller M, de Vries EGE, Jansen PLM. Role of multidrug resistance protein (MRP) in glutathione S-conjugate transport in mammalian cells. J Hepatol 1996, 24(suppl 1):35109-35114.
71. Madon J, Eckhardt U, Gerloff T, Stieger B, Meier PJ. Functional expression of the rat liver canalicular iso-form of the multidrug resistance-associated protein. FEBS Lett 1997, 406:213-215.
72. Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, Stieger B. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 1997, 26:85-131.
73. Surendran N, Covitz KM, Han H, Sadée W, Oh GM, Amidon GL, et al. Evidence for overlapping substrate specificity between large neutral amino acid (LNAA) dipeptide (hPEPT1) transporters for PD 158473 an NMDA antagonist. Pharm Res 1999, 16:1123-1129.
74. Griffith J, Sansom C The transporter factsbook 1998, Academic Press, San Diego.
75. Ambudkar SV, Pastan I, Gottesman MM Cellular and biochemical aspects of multidrug resistance. Drug transport in antimi-crobial and anticancer chemotherapy 1995, 357-362. Marcel Dekker, Inc, New York. G. NH (Ed.).
76. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical cellular and pharmacological aspects of the multidrug trans-porter. Annu Rev Pharmacol Toxicol 1999, 39:89-109.
77. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-Glycoprotein: From genomics to mechanism. Oncogene 2003, 22:1-44.
78. Chang G, Roth CB. Structure of MsbA from E. coli: A homolog of the multidrug resistance ATP bind-ing cassette (ABC) transporters. Science 2001, 293:346-358.
79. Chang G. Structure of MsbA from Vibrio cholera: A multidrug resistance ABC transporter homolog in a closed conformation. J Mol Biol 2003, 330:27-31.
80. Locher KP, Lee AT, Rees DC. The E. coli BtuCD struc-ture: A framework for ABC transporter architecture and mechanism. Science 2002, 296:463-467.
81. Seelig A, Landwojtowicz E, Fischer H, Blatter XL Towards P-glycoprotein structure-activity relation-ships. Methods and Principles of Medicinal Chemistry 2003, vol 18:1680-1688. Chap 20, Wiley-VCH Verlag GmbH & Co, Weinheim. V. de Waterbeemd H, L.-D. H, A. P (Eds.).
82. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 1998, 251:1310-1319.
83. Kaback HR, Sabin-Toth M, einglass AB The kamikaze approach to membrane transport. Nat Rev Mol Cell Biol 1901, 2:199-205.
84. Hirai T, Heymann JAW, Shi D, Sarker R, Maloney PC, Subramaniam S. Three dimensional structure of a bacterial oxalate transporter. Nat Struct Biol 2002, 9:239-261.
85. Abramson J, Smirnova I, Kasho V, Verner G, Kaback HR, Iwata S. Structure and mechanism of the lactose permease of Escherichia coli. Science 2003, 301:1524-1531.
86. Huang Y, Lemieux MJ, Song J, Auer M, Wang DN. Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 2003, 301:408-451.
87. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, et al. 5'-Amino acid esters of antiviral nucle-osides acyclovir and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res 1998, 15:431-460.
88. Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME. Transport of valganciclovir a ganciclovir prodrug via pep-tide transporters PEPT1 and PEPT2. J Pharm Sci 1900, 89:781-789.
89. Curran M, Noble S Valganciclovir. Drugs 2001, 61:100-108.
90. Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant patients. Antimicrob Agents Chemother 2000, 44:75-78.
91. Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, et al. XP13512 [(+/-) -1-([(α-isobutanoyloxyethoxy) carbonyl]aminomethyl) -1-cyclohexane acetic acid] a novel gabapentin prodrug: I. Design synthesis enzymatic. J Pharmacol Exp Ther 2004, 311:1667-1677.
92. Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, et al. XP13512 [(+/-) -1-([(α-isobutanoyloxyethoxy) carbonyl]aminomethyl) -1-cyclohexane acetic acid]a novel gabapentin prodrug: II. Improved oral bioavailabili. J Pharmacol Exp Ther 2004, 311:391-395.
93. Yu DK. The contribution of P-glycoprotein to phar-macokinetic drug-drug interactions. J Clin Pharma-col 1999, 39:525-547.
94. Gramatte T, Oertel R. Intestinal secretion of intra-venous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther 1999, 66:361-398.
95. Eagling VA, Profit L, Black DJ. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 1999, 48:7468-7485.
96. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res 1999, 16:1793-1800.
97. Physiology and pharmacology of the blood-brain barrier. Handbook of experimental pharmacology 1992, vol 103. Springer-Verlag, New York. B. MWB (Ed.).
98. Davson H, Segal M Physiology of the cerebrospinal fluid and blood-brain barrier 1996, 8, CRC Press, Boca Raton, FL.
99. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77:419-430.
100. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997, 94:1091-1098.
101. Schinkel AH, Wagenaar E, Mol CA, Van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996, 97:461-492.
102. Sadeque AJM, Wandel C, He H, Shah S, Wood AJJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000, 68:252-261.
103. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, et al. Choroid plexus epithe-lial expression of MDR1 P-glycoprotein and multi-drug resistance-associated protein contribute to the blood-cerebrospinal fluid drug-per. Proc Natl Acad Sci USA 1999, 96:610-620.
104. Golden PL, Pollack GM. Blood-brain barrier efflux transport. J Pharm Sci. 2003, 92:597-600.
105. Rothem L, Ifergan I, Kaufman Y, Priest DG, Jansen G, Assaraf YG. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate car-rier gene in hu. Biochem J 2002, 367:610-615.
106. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002, 99:616-620.
107. Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin carboplatin and oxaliplatin in ovarian cancer cells. Clin Cancer Res 2004, 10:1154-1159.
108. Gary Kruh. Lustrous insights into cisplatin accumu-lation: Copper transporters. Clin Cancer Res 2003, 9:781-789.
109. Sugeno H, Takebayashi Y, Higashimoto M, Ogura Y, Shibukawa G, Kanzaki A, et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) in human hepatocellular carcinoma. Anti-cancer Res 2004, 24:1145-1150.
110. Lee CGL, Gottesman MM. HIV-1 protease inhibitors and the MDR1 multidrug transporter. J Clin Invest 1998, 101:2811-2815.
111. Subramanian A, Ranganathan P, Diamond SL. Nuclear targeting peptide scaffolds for lipofection of nondividing mammalian cells. Nat Biotechnol 1999, 17:315-323.
112. Gerschenson M, Erhart SW, Paik CY, St Claire MC, Nagashima K, Skopets B, et al. Fetal mitochondrial heart and skeletal muscle damage in Erythroce-bus patas monkeys exposed in utero to 3-azido-3'-deoxythymidine. AIDS Res Hum Retroviruses 2000, 1 6:324-333.
113. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure lactic acidosis due to fialuridine (FIAU) an investi-gational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995, 333:1203-1211.
114. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002, 46:239-245.
115. Cabrita MA, Hobman TC, Hogue DL, King KM, Cass CE. Mouse transporter protein a membrane pro-tein that regulates cellular multidrug resistance is localized to lysosomes. Cancer Res 1999, 59:543-552.
116. Pritchard JB, Miller DS. Renal secretion of organic anions and cations. Kidney Int 1996, 49:478-485.
117. Dresser MJ, Leabman MK, Giacomini KM. Trans-porters involved in the elimination of drugs in the kidney: Organic anion transporters and organic cation transporters. J Pharm Sci 2001, 90:8.
118. Mangravite LM, Badagnani I, Giacomini KM. Nucleo-side tranporters in disposition and targeting of nucleoside analogs in the kidney. Eur J Pharmacol 2003, 479:491-502.
119. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the inter-action between digoxin and quinidine. Circulation 1999, 99:4028-4033.
120. Verschraagen M, Koks CH, Schellens JH, Beijnen JH. P-glycoprotein system as a determinant of drug inter-actions: The case of digoxin-verapamil. Pharmacol Res 1999, 40:2517-2524.
121. Freitag D, Bebee R, Sunderland B. Digoxin-quinidine and digoxin-amiodarone interactions: Frequency of occurrence and monitoring in Australian repatriation hospitals. J Clin Pharm Ther 1995, 20:231-237.
122. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002, 41:3900-3905.
123. Pfister M, Labbe L, Lu JF, Hammer SM, Mellors J, Bennett KK, Rosenkranz S, Sheiner LB, AIDS Clinical Trial Group Protocol 398 investigators. Effect of coad-ministration of nelfinavir indinavir and saquinavir on the pharmacokinetics of amprenavir. Clin Phar-macol Ther 2002, 72:1739-1753.
124. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999, 66:741-750.
125. Fugh-Berman A Herb-drug interactions. Lancet 2000, 355:14298-14302.
126. Fugh-Berman A Herb-drug interactions. Lancet 2000, 355:4661-4669. See also erratum and comment.
127. Scotto KW, Johnson RA. Transcription of the mul-tidrug resistance gene MDR1: A therapeutic target. Mol Interv 2001, 1:5087-5089.
128. Goldstein LJ, Gottesman MM, Pastan I. Expression of MDR1 gene in human cancer. Cancer Treat Res 1991, 57:1045-1048.
129. Goldstein LJ, Pastan I, Gottesman MM. Multidrug resistance in human cancers. Crit Rev Oncol Hematol 1992, 12:287-288.
130. Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, et al. Controlled trial of dexverapamil a modulator of multidrug resistance in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995, 12:873-877.
131. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al. Frequency clinical significance of the expression of mul-tidrug resistance proteins MDR1/P-glycoprotein MRP1 and LRP in acute myeloid leukemia: A Southwest On. Blood 1999, 94:635-644.
132. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremor. Mol Cancer Ther 1902, 1:1099-1105.
133. Licht T, Pastan I, Gottesman MM, Herrmann F. The multidrug-resistance gene in gene therapy of cancer and hematopoietic disorders. Ann Hematol 1996, 72:716-723.
134. Hafkemeyer P, Licht T, Pastan I, Gottesman MM. Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensi-tizer of multidrug-resistant cancers. Hum Gene Ther 2000, 11:4890-4897.
135. Lewis K Multidrug resistance efflux. Transport of molecules across microbial membranes. 58th Symposium of the Soci-ety for General Microbiology, University of Leeds, September 1999 1999, 1649-1654. Cambridge University Press, London. B.-S. JK, B. S, S. CJ, W. FB (Eds.).
136. Sadée W, Graul RC, Lee AY Classification of mem-brane transporters. Membrane transporters as drug targets 1999, 397-421. Kluwer Academic/Plenum Publishers, New York. A. GL, S.-A. W (Eds.).
137. Sadée W. Genomics and drugs: Finding the optimal drug for the right patient. Pharm Res 1998, 15:269-281.
138. Evans WE, Relling MV. Pharmacogenomics: Trans-lating functional genomics into rational therapeutics. Science 1999, 286:552-557.
139. Lee VH, Sporty JL, Fandy TE. Pharmacogenomics of drug transporters: The next drug delivery challenge. Adv Drug Deliv Rev 1901, 50(suppl 1):301-306.
140. Botka CW, Wittig TW, Graul RC, Nielsen CU, Higaka K, Amidon GL, Sadée W Human proton/oligopeptide transporter (POT) genes: Identification of putative human genes using bioinformatics. AAPS PharmSci 2000, 2:E16.
141. Saier MH Jr, Paulsen IT, Sliwinski MK, Pao SS, Skurray RA, Nikaido H. Evolutionary origins of mul-tidrug and drug-specific efflux pumps in bacteria. FASEB J 1998, 12:179-183.
142. Saier MH Jr, Tseng T-T Evolutionary origins of transmembrane transport systems. Transport of molecules across microbial membranes. 58th Symposium of the Society for General Microbiology, University of Leeds, September 1999 1999, 813-851. Cambridge University Press, London.
143. Paulsen IT, Sliwinski MK, Saier MH Jr. Microbial genome analyses: Global comparisons of transport capabilities based on phylogenies bioenergetics and substrate specificities. J Mol Biol 1998, 277:133-141.
144. Paulsen IT, Sliwinski MK, Nelissen B, Goffeau A, Saier MH Jr. Unified inventory of established and putative transporters encoded within the com-plete genome of Saccharomyces cerevisiae. FEBS Lett 1998, 430:338-345.
145. Internet at http://www.chem.qmul.ac.uk/iubmb/mtp.
146. Internet at http://www.gene.ucl.ac.uk/nomenclature.
147. Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. The ABCs of solute car-riers: Physiological pathological and therapeutic implications of human membrane transport proteins Introduction. Pflugers Arch 2004, 447:134-138.
148. Internet at http://www.tcdb.org.
149. Clayton RA, White O, Ketchum KA, Venter JC. The first genome from the third domain of life. Nature 1997, 387:1019-1020.
150. Fraser CM, Norris SJ, Weinstock GM, White O, Sutton GG, Dodson R, et al. Complete genome sequence of Treponema pallidum the syphilis spiro-chete. Science 1998, 281:117-125.
151. Internet at www.tigr.org. A list of known human transporters is given under the heading EGAD Cellular Roles/Metabolism/Transport.
152. Yan Q, Sadée W Human membrane transporter database: A Web-accessible relational database for drug transport studies and pharmacogenomics. AAPS PharmSci 2000, 2:E20. See also. http://www.aapspharmsci.org/view.asp?art=ps020320&pdf=yes;http://lab .digibench.net/transporter.
153. Brown S, Chang JL, Sadée W, Babbitt PC. A semiauto-mated approach to gene discovery through expressed sequence tag data mining: Discovery of new human transporter genes. AAPS PharmSci 2003, 5:E1.
154. Huang Y, Sadée W. Drug sensitivity and resistance genes in cancer chemotherapy: A chemogenomics approach. Drug Discov Today 2003, 8:101-119.
155. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, Reinhold WC, Papp A, Weinstein JN, Sadée W. Membrane transporters and channels: Role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004, 64:243-253.
156. Ross DD, Doyle LA. Mining our ABCs: Pharmacoge-nomic approach for evaluating transporter function in cancer drug resistance. Cancer Cell 2004, 6:1995-2004.
157. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM. Predicting drug sensitivity and resistance: Profiling ABC trans-porter genes in cancer cells. Cancer Cell 2004, 6:1086-1099.
158. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM. Predicting drug sensitivity and resistance: Profiling ABC trans-porter genes in cancer cells. Cancer Cell 2004, 6:417-425. Comment in.
159. Sun D, Lennernäs H, Welage LS, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD, Amidon GL. Comparison of human duodenum Caco-2 gene expression profiles for 12000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res 2002, 19:184-193.
160. Choi KH, Chen CJ, Kriegler M, Roninson IB. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 1988, 53:555-565.
161. Kioka N, Tsubota J, Kakehi Y, Komano T, Gottesman MM, Pastan I, et al. P-glycoprotein gene (MDR1) cDNA from human adrenal: Normal P-glycoprotein carries Gly185 with an altered pat-tern of multidrug resistance. Biochem Biophys Res Commun 1989, 162:15-40.
162. Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, et al. Genetic polymorphism in MDR-1: A tool for examining allelic expression in normal cells unselected drug-selected cells and human tumors. Blood 1998, 91:29-58.
163. Umbenhauer DR, Lankas GR, Pippert TR, Wise LD, Cartwright ME, Hall SJ, et al. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length poly-morphism. Toxicol Appl Pharmacol 1997, 146:959-963.
164. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymor-phisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression an. Proc Natl Acad Sci USA 2000, 97:487-491.
165. Woodahl EL, Ho RJ. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 2004, 5:S33-S40.
166. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001, 70:E16.
167. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Swiss HIV Cohort Study. Lancet 2002, 359:265-274.
168. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Swiss HIV Cohort Study. Lancet 2002, 359:2114. Comment in.
169. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Swiss HIV Cohort Study. Lancet 2002, 359:252-274.
170. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, et al. Pharmacogenetics of membrane transporters investigators. Pharmacoge-netics 2003, 13:573-592.
171. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, et al. Pharmacogenetics of membrane transporters investigators. Pharmacogenetics 2003, 13:701. Erratum in.
172. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, Schuetz EG. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003, 13:116-125.
173. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, McLeod HL. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 2004, 76:465-468.
174. De Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, McLeod HL. ABCG2 phar-macogenetics: Ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 2004, 10:459-462.
175. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. Expression up-regulation and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 2004, 64:375-388.
176. Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E, et al. Identification of genetic variations of the human organic cation trans-porter hOCT1 and their functional consequences. Pharmacogenetics 2002, 12:E20.
177. Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, et al. Polymorphisms in a human kidney xenobiotic transporter OCT2 exhibit altered function. Pharmacogenetics 2002, 12:E1.
178. Schinkel AH, Jonker JW. Polymorphisms affecting function of the human organic cation transporter hOCT1 (SLC22A1): What are the consequences?. Phar-macogenetics 2002, 12:356-363.
179. Tirona RG, Leake BF, Merino G, Kim RB. Polymor-phisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J Biol Chem 2001, 276:4294-4301.
180. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003, 73:129-137.
181. Tirona RG, Kim RB. Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv Drug Deliv Rev 2002, 54:105-107.
182. Marzolini C, Tirona RG, Kim RB. Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 2004, 5:129-137.
183. Leabman MK, Huang CC, De Young J, Carlson EJ, Taylor TR, de la Cruz M, et al. Natural variation in human membrane transporter genes reveals evolu-tionary and functional constraints. Proc Natl Acad Sci USA 2003, 100:1400-1416.
184. Gray JH, Mangravite LM, Owen RP, Urban TJ, Chan W, Carlson EJ, et al. Functional genetic diversity in the concentrative nucleoside transporter CNT1in human populations. Mol Pharmacol 2004, 65:519-529.
185. Van de Waterbeemd H, Lennernäs H, Artursson P Drug bioavailability - estimation of sol-ubility, permeability, absorption and bioavailability. Methods and principles of medicinal chemistry 2003, vol 18. Wiley-VCH Verlag GmbH & Co., Weinheim.
186. Winiwarter S, Ax F, Lennernäs H, Hallberg A, Pettersson C, Karlen A. Hydrogen bonding descrip-tors in the prediction of human in vivo intestinal permeability. J Mol Graph Model 2003, 21:224-231.
187. Krarup LH, Christensen IT, Hovgaard L, Frokjaer S. Predicting drug absorption from molecular surface properties based on molecular dynamics simulations. Pharm Res 1998, 15:1749-1756.
188. Iyer M, Mishru R, Han Y, Hopfinger AJ. Predicting blood-brain barrier partitioning of organic molecules using membrane-interaction QSAR analysis. Pharm Res 2002, 19:88-94.
189. Bolger MB Computational methods to predict biopharmaceutical properties. AAPS meeting, Indianapolis 2000, Internet at. http://www.simulations-plus.com/pdf_files/aaps_2000_report.pdf.
190. KnowItAll ADME/Tox Blood-Brain Barrier Permeability Predictor. (Internet at http://biorad.com/pages/SAD/collateral/predictors_blood_brain_barrier.pd f.).
191. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug clas-sification the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995, 12:3473-3478.
192. Chang C, Ray A, Swaan P. In silico strategies for modeling membrane transporter function. Drug Discov Today 2005, 10:11-19.